Tagged with

China Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market.   Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers…

China Dr Yi (York) Chen, VP for operations and commercial planning at Arctic Vision shares his priorities, his wide experience of ophthalmology product launches in China, and how the company is positioning itself in relation to much larger companies in the Chinese ophthalmology market.   Fundamentally, we are convinced that the…

Novartis In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) to Pia Boehnke, a Belgian child.   With Zolgensma® at that point having not yet been authorised by the European…

Algeria Below we present recent news from Algeria’s pharmaceutical industry, including the creation of a dedicated Ministry to boost the sector, changes to the advertising rules for dietary supplements, and local medical device manufacturers’ efforts in the fight against COVID-19.   Government: Broad prerogatives for the newly created Ministry of Pharmaceutical…

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion.   By now, we have a platform of over 500…

Merck Teresa Rodó gives an overview of her role overseeing the development, manufacturing, supply, and quality of all of Merck’s biotech and pharmaceutical medicines and medical devices. Rodó also explains how the company has been able to withstand the supply chain challenges posed by the COVID-19 pandemic, and why Merck is…

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

Talent A new report by Novartis looks at how leading talent in the technology industry is increasingly looking to bring their skillsets into the healthcare and life sciences industries against the backdrop of the fight against COVID-19.   Top tech talent sees a myriad of opportunities to leverage its knowledge in…

Roundup A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine candidate, and more.   Boehringer creates Shanghai hub to connect with Chinese R&D groups https://www.fiercebiotech.com/biotech/boehringer-creates-shanghai-hub-to-connect-chinese-r-d-groups With China’s domestic biotech scene…

AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…